7 articles
Novo Nordisk faces investor pressure to diversify beyond its blockbuster weight-loss drugs amid rising competition from Eli Lilly and impending semaglutide patent expiries. Analysts suggest acquisitio
Novo Nordisk reported that 40.4% of children aged 6 to under 12 treated with semaglutide were no longer classified as obese after 68 weeks in the STEP Young trial. Safety profiles remained consistent
New research shows semaglutide extends lifespan and delays aging in mice, indicating potential new indications for the popular GLP-1 agonist beyond weight loss and diabetes treatment.
Indian shares opened little changed after the Federal Reserve held rates steady, amidst geopolitical risks pushing Brent crude lower. Meanwhile, Sun Pharma gained approval to manufacture semaglutide i
Dr Reddy's shares fell nearly 7% as brokerages cut forecasts due to weak margins and semaglutide supply disruptions lasting until late October. Analysts indicate recovery depends on supply resumption
Dr Reddy's Q1 profit plunged 68.7% to 4.44 billion rupees due to semaglutide inventory costs stemming from an active ingredient impurity. Revenue dropped 5.5% amidst pricing pressures and market compe
Dr Reddy's shares fell after halting semaglutide injections due to an API impurity. Analysts downgraded earnings forecasts, warning the supply disruption could erode the company's market advantage.
ChemBrief